MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic X Syndrome Dyslipidemia
Conditions
Metabolic X Syndrome Dyslipidemia
Trial Timeline
Jan 1, 2002 → Dec 1, 2003
NCT ID
NCT00703690About MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified) is a phase 2 stage product being developed by Merck for Metabolic X Syndrome Dyslipidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00703690. Target conditions include Metabolic X Syndrome Dyslipidemia.
What happened to similar drugs?
19 of 20 similar drugs in Metabolic X Syndrome Dyslipidemia were approved
Approved (19) Terminated (4) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00703690 | Phase 2 | Terminated |
Competing Products
20 competing products in Metabolic X Syndrome Dyslipidemia